{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-006190","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.714639+00:00","generated_at":"2026-05-28T02:33:18.625556+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025","bullets":["Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.","Employment agreement: $1M base salary, $2M one-time cash retention award, annual bonus target 150% of salary.","Equity transformation award: 640,000 performance share units with stock price hurdles of 125%, 150%, and 175%.","Annual equity grants of at least $5.5M; severance for cause-less termination: 2x base+bonus, 3x under change in control.","Dr. Swift's departure is termination without cause; he will receive severance benefits under prior employment agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-006190","json":"https://secwatch.observer/filing/0001193125-25-006190.json","markdown":"https://secwatch.observer/filing/0001193125-25-006190.md","text":"https://secwatch.observer/filing/0001193125-25-006190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/0001193125-25-006190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/d855972d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:33:18.625556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f93309868","claim":"Mark S. Ordan was appointed as Chief Executive Officer at Pediatrix Medical Group, Inc..","evidence_excerpt":"appointed Mr. Mark S. Ordan to serve as the Company’s Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/0001193125-25-006190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}]},{"claim_id":"7ac2d74f12","claim":"Dr. James D. Swift departed as other_named_officer at Pediatrix Medical Group, Inc..","evidence_excerpt":"succeeding Dr. James D. Swift.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/0001193125-25-006190-index.htm","confidence":0.75,"family_label":"Executive change","details":[]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}